Apnimed will apply the IPO proceeds toward the regulatory process and launch plans of Oxnimbi, a once-nightly pill developed for obstructive sleep apnea. This drug is under FDA review with a February 2027 target date for a regulatory decision.
The post Apnimed’s IPO Bags $192M for What Could Become the First Oral Sleep Apnea Drug appeared first on MedCity News.
